| 
        (V1835) | 
        Association of medication adherence and depression with control of LDL cholesterol and blood pressure in patients with high cardiovascular risk | 
      
      
        |   | 
          | 
        J. Katzmann, F. Mahfoud, M. Böhm, M. Schulz, U. Laufs  (Leipzig, Homburg/Saar, Berlin) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1836) | 
        The role of lipoprotein a as a cardiovascular risk factor in primary prevention screening | 
      
      
        |   | 
          | 
        J. Gilis-Januszewski, R. Gottfried-Kwasniok, T. Gilis-Januszewski, K.-P. Mellwig, V. Rudolph  (Bad Oeynhausen) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1837) | 
        No association of plasma levels of markers for cholesterol homeostasis and cumulative future cardiovascular events | 
      
      
        |   | 
          | 
        O. Weingärtner, A. Fuhrmann, S. Meyer, B. Cremers, S. Seiler-Mussler, A. Kerksiek, A. Friedrichs, A. Zawada, U. Laufs, B. Scheller, C. Schulze, D. Fliser, M. Böhm, G. Heine, D. Lütjohann  (Jena, Bonn, Oldenburg, Homburg (Saar), Leipzig) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1838) | 
        Endothelial function assessed by digital volume plethysmography predicts the development and progression of type 2 diabetes mellitus | 
      
      
        |   | 
          | 
        O. Hahad, P. S. Wild, J. Prochaska, A. Schulz, T. Gori, T. Münzel, für die Studiengruppe: GHS (Mainz) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1839) | 
        Schutz vor Insulinresistenz und Adipositas durch Deletion der Sphingosin-1-Phosphat Lyase | 
      
      
        |   | 
          | 
        S. Weske, P. Keul, K. von Wnuck Lipinski, M. Vaidya, G. Heusch, B. Levkau  (Essen) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1840) | 
        Blocking the purinergic P2Y13 receptor signalling improves the outcome of metabolic syndrome in mice | 
      
      
        |   | 
          | 
        K. Rofa, J. Merz, N. Hoppe, I. Ahmed, D. Dimanski, B. Dufner, I. Hilgendorf, C. Bode, A. Zirlik, P. Stachon  (Freiburg im Breisgau; Graz, AT) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1841) | 
        Hematopoietic alterations in chronic heart failure patients by somatic mutations leading to clonal hematopoiesis | 
      
      
        |   | 
          | 
        L. Dorsheimer, B. Aßmus, C. A. Ortmann, T. Rasper, K. Abou-El-Ardat, J. Hoffmann, F. Seeger, S. Dimmeler, A. M. Zeiher, M. Rieger, H. Bönig  (Frankfurt am Main, Ravensburg) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1842) | 
        Promotion of Arterial Stiffness by Childhood Cancer and its Characteristics in Adult Long-term Survivors | 
      
      
        |   | 
          | 
        N. Arnold, H. Merzenich, A. Wingerter, A. Schulz, A. Schneider, J. Prochaska, S. Göbel, M.-A. Neu, N. Henninger, M. Panova-Noeva, C. Spix, I. Schmidtmann, K. J. Lackner, M. Beutel, N. Pfeiffer, T. Münzel, J. Faber, P. S. Wild  (Mainz) | 
      
      
         | 
         | 
        Diskussion | 
      
      
         | 
        (V1843) | 
        Analysis of novel cardiovascular biomarkers in patients with chronic kidney disease | 
      
      
        |   | 
          | 
        M. Mirna, A. Topf, B. Wernly, V. Paar, P. Jirak, U. C. Hoppe, C. Jung, M. Franz, C. Schulze, M. Lichtenauer, D. Kretzschmar  (Salzburg, AT; Düsseldorf, Jena) | 
      
      
         | 
         | 
        Diskussion |